Bayer and Iambic partner on AI-driven small molecule drug discovery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
June 22, 2026 8:00 AM EDTCollaboration focuses on small molecule discovery Bayer to leverage Iambics AI platform to address hard-to-drug targets Collaboration will strengthen Bayers research and development portfolio by harnessing AI to accelerate drug discovery
BERLIN & SAN DIEGO--(BUSINESS WIRE)-- Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambics AI-driven platform. The collaboration is focused on small molecule discovery.
The collaboration will leverage Iambics AI-driven drug discovery... More
